Research graph
References from Vericiguat responders vs. non-responders: what determines the difference in treatment response?. Local targets link to admitted publications; unresolved targets remain external evidence.
Non-invasive hemodynamic and echocardiographic changes following vericiguat initiation in heart failure with reduced ejection fraction: a prospective registry study
2000 · External reference
Evaluating haemodynamic changes: vericiguat in patients with heart failure with reduced ejection fraction
10.1002/ehf2.14802 · 2024 · External reference
Vericiguat: VICTORy or defeat?
10.1016/j.jchf.2025.102763 · 2026 · External reference
Vericiguat and NT-proBNP in patients with heart failure with reduced ejection fraction: analyses from the VICTORIA trial
10.1002/ehf2.14050 · 2022 · External reference
Age, sex, and outcomes in heart failure with reduced EF: insights from the VICTORIA trial
10.1016/j.jchf.2023.06.020 · 2023 · External reference
Armstrong PW; for the VICTORIA Study Group. Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the VICTORIA (Vericiguat Global Study in Subjects with HFrEF) trial
10.1002/ejhf.2221 · 2021 · External reference
Ejection fraction, biomarkers, and outcomes and impact of vericiguat on outcomes across EF in VICTORIA
10.1016/j.jchf.2022.12.014 · 2023 · External reference
Clinical outcomes and response to vericiguat according to index heart failure event: insights from the VICTORIA trial
10.1001/jamacardio.2020.6455 · 2021 · External reference
Assessment of biomarkers of myocardial injury, inflammation, and renal function in heart failure with reduced ejection fraction: The VICTORIA biomarker substudy
10.1016/j.cardfail.2022.12.013 · 2023 · External reference
Assessing benefit in patients with heart failure and reduced ejection fraction: analysis of the VICTORIA trial using novel prognostic risk stratification
2025 · External reference
